BACKGROUND: There is controversy regarding the optimal type of lung transplant--single orthotopic lung transplantation (SOLT) versus bilateral orthotopic lung transplantation (BOLT)--for patients with idiopathic pulmonary fibrosis. We performed this study to determine which type of transplant is more appropriate for older patients with this condition. METHODS: We conducted a review of the United Network for Organ Sharing database from 2005 to 2013 for patients aged 65 years or more with idiopathic pulmonary fibrosis. A 1:1 nearest-neighbor propensity match was utilized to determine differences in survival by transplant procedure type (SOLT versus BOLT). Logistic regression modeling taking into account interaction terms between prespecified variables and the type of transplant was utilized to determine variables that altered the survival outcomes associated with SOLT versus BOLT. RESULTS: Of 1,564 patients who met study criteria, 521 (33.3%) received BOLT. After propensity matching 498 BOLT recipients to 498 SOLT recipients, BOLT was associated with a significantly improved 5-year survival (48.7% versus 35.2%, p < 0.01). However, the mortality hazard associated with BOLT varied from a nonsignificant reduction in survival within 3 months after transplant (hazard ratio 1.24, 95% confidence interval: 0.80 to 1.93) to a significant survival benefit for patients who survived beyond 1 year (hazard ratio 0.64, 95% confidence interval: 0.47 to 0.86). Functional status was also found to be a significant predictor of the survival benefit associated with BOLT. CONCLUSIONS: Bilateral orthotopic lung transplantation is associated with significantly improved survival over SOLT for older patients with idiopathic pulmonary fibrosis, driven by a late survival benefit from bilateral transplantation. However, patients with a reduced preoperative functional status do not appear to derive a similar benefit from bilateral transplantation.
BACKGROUND: There is controversy regarding the optimal type of lung transplant--single orthotopic lung transplantation (SOLT) versus bilateral orthotopic lung transplantation (BOLT)--for patients with idiopathic pulmonary fibrosis. We performed this study to determine which type of transplant is more appropriate for older patients with this condition. METHODS: We conducted a review of the United Network for Organ Sharing database from 2005 to 2013 for patients aged 65 years or more with idiopathic pulmonary fibrosis. A 1:1 nearest-neighbor propensity match was utilized to determine differences in survival by transplant procedure type (SOLT versus BOLT). Logistic regression modeling taking into account interaction terms between prespecified variables and the type of transplant was utilized to determine variables that altered the survival outcomes associated with SOLT versus BOLT. RESULTS: Of 1,564 patients who met study criteria, 521 (33.3%) received BOLT. After propensity matching 498 BOLT recipients to 498 SOLT recipients, BOLT was associated with a significantly improved 5-year survival (48.7% versus 35.2%, p < 0.01). However, the mortality hazard associated with BOLT varied from a nonsignificant reduction in survival within 3 months after transplant (hazard ratio 1.24, 95% confidence interval: 0.80 to 1.93) to a significant survival benefit for patients who survived beyond 1 year (hazard ratio 0.64, 95% confidence interval: 0.47 to 0.86). Functional status was also found to be a significant predictor of the survival benefit associated with BOLT. CONCLUSIONS: Bilateral orthotopic lung transplantation is associated with significantly improved survival over SOLT for older patients with idiopathic pulmonary fibrosis, driven by a late survival benefit from bilateral transplantation. However, patients with a reduced preoperative functional status do not appear to derive a similar benefit from bilateral transplantation.
Authors: Fernando J Martinez; Sharon Safrin; Derek Weycker; Karen M Starko; Williamson Z Bradford; Talmadge E King; Kevin R Flaherty; David A Schwartz; Paul W Noble; Ganesh Raghu; Kevin K Brown Journal: Ann Intern Med Date: 2005-06-21 Impact factor: 25.391
Authors: D E Low; E P Trulock; L R Kaiser; M K Pasque; C Dresler; N Ettinger; J D Cooper Journal: J Thorac Cardiovasc Surg Date: 1992-06 Impact factor: 5.209
Authors: David J Lederer; Selim M Arcasoy; Jessie S Wilt; Frank D'Ovidio; Joshua R Sonett; Steven M Kawut Journal: Am J Respir Crit Care Med Date: 2006-06-15 Impact factor: 21.405
Authors: Dan M Meyer; Leah Bennett Edwards; Fernando Torres; Michael E Jessen; Richard J Novick Journal: Ann Thorac Surg Date: 2005-03 Impact factor: 4.330
Authors: Gabriel Thabut; Jason D Christie; Philippe Ravaud; Yves Castier; Olivier Brugière; Michel Fournier; Hervé Mal; Guy Lesèche; Raphaël Porcher Journal: Lancet Date: 2008-03-01 Impact factor: 79.321
Authors: Coenraad F N Koegelenberg; Gillian M Ainslie; Keertan Dheda; Brian W Allwood; Michelle L Wong; Umesh G Lalloo; Mohamed S Abdool-Gaffar; Hoosain Khalfey; Elvis M Irusen Journal: J Thorac Dis Date: 2016-12 Impact factor: 2.895
Authors: M G Hartwig; A M Ganapathi; A A Osho; S A Hirji; B R Englum; P J Speicher; S M Palmer; R D Davis; L D Snyder Journal: Am J Transplant Date: 2016-07-15 Impact factor: 8.086
Authors: Christopher M Bobba; Bryan A Whitson; Matthew C Henn; Nahush A Mokadam; Brian C Keller; Justin Rosenheck; Asvin M Ganapathi Journal: Transpl Int Date: 2022-04-04 Impact factor: 3.842
Authors: Christopher L Mosher; Jeremy M Weber; Courtney W Frankel; Megan L Neely; Scott M Palmer Journal: J Heart Lung Transplant Date: 2020-10-31 Impact factor: 10.247